Taizhou Beijin Biotechnology Co., Ltd.

Using Jinyouli® as a positive control, the efficacy, safety and immunogenicity of MW05 in preventing chemotherapy-induced neutropenia in breast cancer patients were compared.

Main research objectives To evaluate the tolerability and safety of GW003 in breast cancer patients. Secondary research objectives To reveal the pharmacokinetic/pharmacodynamic characteristics of GW003 in breast cancer patients and recommend a reasonable dosing regimen and basis for Phase II clinical studies. To reveal the preliminary efficacy of GW003 in breast cancer patients.

Main research purpose: To evaluate the tolerability and safety of a single dose of GW003 in healthy Chinese subjects. Secondary research purpose: To reveal the pharmacokinetic/pharmacodynamic characteristics of GW003 in healthy subjects and recommend a reasonable dosing regimen and basis for Phase I and Phase II clinical studies.